ACTRN12612000729820
Completed
Phase 1
Patients with atrophic age-related macular degeneration and the effect of saffron supplementation compared with placebo in improving visual and electrophysiological outcomes
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- The University of Sydney
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of age\-related macular degeneration (AMD) as determined by a qualified retinal specialist
- •Ability to participate in electroretinographic examination
Exclusion Criteria
- •Significant ocular media opacities
- •Other retinal disease (i.e. diabetes, glaucoma, retinal vascular disease)
- •Neovascular AMD
- •Presence of small bowel or liver disease impairing oral tablet absorption
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Research on age-related macular degeneration and diabetic complications using non-invasive AGEs measurement equipment.age-related macular degeneration, diabetic retinopathyJPRN-UMIN000010741Shinshu University Graduate School of Medicine, Department of Ophthalmology500
Not yet recruiting
Not Applicable
Fellow Eye Effect with Ranibizumab for Age Related Macular DegeneratioACTRN12607000575437Monash University25
Completed
Not Applicable
Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU BrugmannAge-related Macular DegenerationNCT04891835Laurence Postelmans36
Completed
Not Applicable
Implementing elements of the Chronic Care Model (CCM) in the care for neovascular age-related macular degeneration (wet AMD): Is it superior to usual care?Age-related macular degeneration (wet AMD)Eye DiseasesISRCTN32507927niversity Hospital Zurich (Universitaetsspital Zurich) (Switzerland)352
Unknown
Not Applicable
Therapy of Age-related Macular DegenerationAge-Related Macular DegenerationNCT05222997Robert Hörantner150